CORBUS PHARMACEUTICALS HOLDI (CRBP)

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company is headquartered in Norwood, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2014-10-24. The firm's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The firm does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.

Company Info

CORBUS PHARMACEUTICALS HOLDI

500 River Ridge Drive

Norwood MASSACHUSETTS 02062

P: 16179630103

CEO: Yuval Cohen

Employees: 19

Website: https://www.corbuspharma.com/